In the beginning of this week Amarillo Biosciences, Inc. (OTC:AMAR) got the climb, though yesterday its stock prize suddenly 
froze up. However, today AMAR looks ready to get the up move again by all means.
Yesterday, Amarillo reported that it has formed an alliance with Bio-Stasis International, Inc. to launch the dietary supplement Virapress. According to the announcement, Bio-Stasis plans to embark on an extensive internet marketing program for Virapress on August 1 this year, targeting alternative and complimentary medical practitioners.
However, the good news was not the only device for chasing the gain. Apart from the positive announcement, yesterday AMAR was heavily promoted by a number of websites for a total compensation of $10.000. The paying party remained unknown, though it was crystal clear that Amarillo is desperate to climb up again.[BANNER]
So far, so good, though there is a bigger issue facing the company – its poor financials. The results show that as of March 31 this year the current liabilities of AMAR are far beyond its current assets, and the stockholders’ equity is a negative value. At the same time, Amarillo has no sufficient cash to cover its liabilities, which might be crucial for its existence.
Based on these facts, even if AMAR gets the climb today, it certainly won’t be enough to ensure the company’s future operation.
